Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Current Treatment Options in Oncology

• Publication date

  2020-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11864-020-0710-xPMID 32318829
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

  2019cited by this paper
• Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.

  2019cited by this paper
• Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

  2019cited by this paper
• Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia

  2019cited by this paper
• Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

  2019cited by this paper
• Cancer treatment and survivorship statistics, 2019

  2019cited by this paper
• Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study

  2019cited by this paper
• Maintenance therapy in AML: The past, the present and the future

  2019cited by this paper
• Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.

  2019cited by this paper
• Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.

  2018cited by this paper
• Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

  2018cited by this paper
• Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML

  2018cited by this paper
• Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.

  2018cited by this paper
• Sorafenib Combined with 5‐azacytidine in Older Patients with Untreated FLT3‐ITD Mutated Acute Myeloid Leukemia

  2018cited by this paper
• CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

  2018cited by this paper
• Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

  2018cited by this paper
• Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions

  2018cited by this paper
• Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

  2018cited by this paper
• Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

  2018cited by this paper
• Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

  2017cited by this paper
• Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

  2017cited by this paper
• Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

  2017cited by this paper
• Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

  2017cited by this paper
• Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

  2016cited by this paper
• Isocitrate dehydrogenase mutations in myeloid malignancies

  2016cited by this paper
• TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

  2016cited by this paper
• The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

  2016cited by this paper
• TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

  2016cited by this paper
• Genomic Classification and Prognosis in Acute Myeloid Leukemia.

  2016cited by this paper
• Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations

  2015cited by this paper
• Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

  2015cited by this paper
• International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

  2015cited by this paper
• APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells

  2015cited by this paper
• Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

  2015cited by this paper
• Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.

  2015cited by this paper
• TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution

  2015cited by this paper
• FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 Inhibitors

  2015cited by this paper
• Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

  2015cited by this paper
• Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

  2014cited by this paper
• Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

  2014cited by this paper
• Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG‐GO) as front‐line regimen in patients with core binding factor acute myelogenous leukemia

  2014cited by this paper
• Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

  2014cited by this paper
• PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance.

  2014cited by this paper
• High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.

  2014cited by this paper
• Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

  2013cited by this paper
• APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

  2013cited by this paper
• MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.

  2013cited by this paper
• Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

  2012cited by this paper
• TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.

  2012cited by this paper
• Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

  2012cited by this paper
• Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.

  2012cited by this paper
• A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

  2012cited by this paper
• Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial

  2012cited by this paper
• Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia.

  2012cited by this paper
• The Feasibility of Inpatient Geriatric Assessment for Older Adults Receiving Induction Chemotherapy for Acute Myelogenous Leukemia

  2011cited by this paper
• Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

  2011cited by this paper
• First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

  2011cited by this paper
• Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

  2010cited by this paper
• Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.

  2010cited by this paper
• Reasons for treating secondary AML as de novo AML

  2010cited by this paper
• The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

  2010cited by this paper
• PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.

  2009cited by this paper
• Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

  2009cited by this paper
• Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

  2009cited by this paper
• FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.

  2008cited by this paper
• Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.

  2008cited by this paper
• FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.

  2007cited by this paper
• Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.

  2007cited by this paper
• Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

  2006cited by this paper
• Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

  2006cited by this paper
• Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

  2005cited by this paper
• Developing a cancer‐specific geriatric assessment

  2005cited by this paper
• Signal Transduction of Oncogenic Flt3

  2005cited by this paper
• Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis

  2005cited by this paper
• The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.

  2004cited by this paper
• Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia

  2004cited by this paper
• Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia.

  2003cited by this paper
• Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.

  2003cited by this paper
• The roles of FLT3 in hematopoiesis and leukemia.

  2002cited by this paper
• Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

  2002cited by this paper
• Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

  2002cited by this paper
• FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.

  2002cited by this paper
• Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

  2001cited by this paper
• Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.

  2000cited by this paper
• Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

  1999cited by this paper
• c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities.

  1998cited by this paper
• On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.

  1989cited by this paper
• Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features.

  1986cited by this paper

• Synthesis and Anti-acute Myeloid Leukemia Activity of Cyclopropane-1,1-diamide Derivatives Containing Imidazo[1,2-a]pyridine

  2025cites this paper
• Identification of prognostic and driver gene mutations in acute myeloid leukemia by a bioinformatics analysis

  2023cites this paper
• High expression of TARP correlates with inferior FLT3 mutations in non-adolescents and young adults with acute myeloid leukaemia

  2021cites this paper
• LncRNA CD27-AS1 promotes acute myeloid leukemia progression through the miR-224-5p/PBX3 signaling circuit

  2021cites this paper
• Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.

  2019cites this paper
• Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

  2018cites this paper